av Kristofer | 25 juni, 2026
StemSight develops off-the-shelf regenerative cell therapies for corneal blindness. Our expertise is in the combination of iPS-derived cells with functional biomaterials – for faster tissue regeneration, safer cell therapies and easier cell delivery.
av Kristofer | 23 juni, 2026
Solid IO is developing a patient-specific tumor-on-chip platform that uses living tumor tissue to predict how individual cancer patients will respond to different therapies. By enabling functional drug testing before treatment begins, the company aims to improve...
av Kristofer | 22 maj, 2026
Specializing in the development of next generation single domain antibodies. Mesenkia is a pre-clinical company developing the next-generation biological drug candidates designed to treat the aggressive brain tumor glioblastoma.
av Kristofer | 10 mars, 2026
CubaseBio enables true 3D spatial analysis at scale, unlocking unprecedented biological insights and accelerating drug discovery.
av Kristofer | 27 oktober, 2025
Abarceo Pharm is a pre-clinical stage company, developing a platform for the treatment of mitochondrial diseases, with an initial focus on Type 2 Diabetes (T2D).
